[mTOR inhibitors, autophagia and Cancer: looking forward to a universal financial coverage]

Rev Med Chil. 2019 May;147(5):674-676. doi: 10.4067/S0034-98872019000500674.
[Article in Spanish]
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use*
  • Autophagy / physiology*
  • Everolimus / economics
  • Everolimus / therapeutic use
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Sirolimus / analogs & derivatives
  • Sirolimus / economics
  • Sirolimus / therapeutic use
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • TOR Serine-Threonine Kinases / metabolism*

Substances

  • Antineoplastic Agents
  • temsirolimus
  • Everolimus
  • TOR Serine-Threonine Kinases
  • Sirolimus